Abstract P4-10-14: Association between depression and anxiety status of breast cancer patients undergoing adjuvant chemotherapy and chemotherapy-induced adverse events

Abstract Background: Breast cancer is the largest malignant tumor threatening women's health. Adjuvant chemotherapy is an important treatment to improve the survival and prognosis of patients. Numerous studies have confirmed that breast cancer is related to emotion and psychology, and patients diagnosed with breast cancer are more likely to have psychological problems. Anxiety, depression and other psychological problems might lead to a decrease in immune function, reducing the patient's tolerance to chemotherapy. This study explored the relationship between anxiety, depression and adverse events during adjuvant chemotherapy in Chinese breast cancer patients. Patients and Methods:This prospective study enrolled 270 Chinese postoperative early breast cancer patients. The clinicopathological characteristics of patients were collected, and the psychological status of depression and anxiety before chemotherapy and after 2 cycles of chemotherapy were assessed by the Hospital Anxiety and Depression Scale(HADS). Adverse events that occurred throughout the course of chemotherapy included myelosuppression, anemia, gastrointestinal events(diarrhea,nausea,vomiting, stomatitis ), alopecias, neurotoxicity, elevated aminotransferase levels, and were graded and recorded according to CTCAE 4.02.Results: In total, 264 valid cases were analyzed. At baseline, the detection rates of depression and anxiety were 20.83%(55/264) and 32.58%(86/264). The mean (95% CI) HADS depression score was 4.73 (1.16, 8.30), and mean anxiety score was 6.14 (2.59, 9.69) . After 2 cycles of chemotherapy, the detection rates of depression and anxiety in chemotherapy were 26.14%(69/264) and 30.30%(80/264). The mean (95% CI) HADS depression score was 5.28 (1.43, 9.13), and mean anxiety score was 5.89 (2.48, 9.30). The incidence of grade two or more myelosuppression induced by chemotherapy was correlated with depression before chemotherapy(P=0.017) and after 2 cycles of chemotherapy(P=0.022). Age, chemotherapy cycles, and pre-chemotherapy depression status were included in multivariate analysis, and showed that incidence of grade two or more myelosuppression induced by chemotherapy was significant related to the pre-chemotherapy depression status(P=0.026). There was no statistical significance between depression and anxiety status and other adverse events (P>0.005). Conclusions: The depression status of breast cancer patients before chemotherapy was correlated with the incidence of grade two or more myelosuppression throughout the course of chemotherapy, and these populations are more likely to develop myelosuppression. It suggests that oncologist should pay more attention to monitoring the depression status of breast cancer patients before chemotherapy, and strengthen the management of adverse events during chemotherapy, so as to ensure the safety of patients and improve the tolerance of chemotherapy. Citation Format: Dan Lv, Bo Lan, Li Zhang, Xiaoying Sun, Min Yang, Fei Ma. Association between depression and anxiety status of breast cancer patients undergoing adjuvant chemotherapy and chemotherapy-induced adverse events [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-10-14.